【FDA批准阿斯利康畅销药物Imfinzi治疗有限期小细胞肺癌】财联社12月5日电，美国食品药品监督管理局(FDA)周三表示，已批准阿斯利康上市重磅药物Imfinzi用于治疗部分成人有限期小细胞肺癌。这种化学上被称为durvalumab的治疗方法被批准用于接受化疗和放疗后疾病没有恶化的患者。

【FDA批准阿斯利康畅销药物Imfinzi治疗有限期小细胞肺癌】美国食品药品监督管理局(FDA)周三表示，已批准阿斯利康上市重磅药物Imfinzi用于治疗部分成人有限期小细胞肺癌。这种化学上被称为durvalumab的治疗方法被批准用于接受化疗和放疗后疾病没有恶化的患者。

Verition Fund Management LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 66.0% in the third ...

Martin Dietrich, MD, PhD, discusses how the FDA-approved combination therapy is transforming care for resectable early-stage ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...

Dec. 5, 2024 — Mangroves have been shown to provide $855 billion in flood protection services worldwide, according to a new ... Dec. 4, 2024 — Coconut palms are king throughout the tropics ...

小细胞肺癌 （SCLC） 是一种恶性程度高、侵袭性强的肺癌亚型，整体预后极差。据《中国肿瘤临床》，全球每年有超过20万例患者新发确诊SCLC，约占肺部恶性肿瘤总发病率的15%～20%，其中30%～40%处于局限期 （LS-SCLC） ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking expanded use of its blockbuster drug, Imfinzi ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...